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PHOSPHONATED AGENTS AND THEIR
ANTIANGIOGENIC AND
ANTITUMORIGENIC USE

effective amount of a phosphonic acid substituted agent to a

CROSS REFERENCE TO RELATED
APPLICATION

patient in need of said treatment.
In another embodiment the invention provides a method

This application is a divisional of application Ser. No.
09/121,124 ?led Jul. 23, 1998, Which is a continuation-in

of inhibiting angiogenesis comprising the steps of adminis

In an embodiment, the invention provides methods of

treating tumors comprising the steps of administering an

tering an effective amount of a phosphonic acid substituted
agent to a patient in need of said treatment.

part of application Ser. No. 08/899,996 ?led Jul. 24, 1997,
noW abandoned.
10

FIELD OF THE INVENTION

The present invention relates to phosphonic acid agents
that are potent inhibitors of angiogenesis and tumorigenesis.

and methods for use of the compositions as potent inhibitors

BACKGROUND ART

Angiogenesis is an essential component of tumor groWth

15

and metastasis. As revieWed by Folkman (1985), the groWth
of solid tumors is dependent on angiogenesis. Typically
20

25

eration With turnover times of a feW days during the groWth
of neW capillaries. Angiogenesis-dependent diseases such as
tumor groWth and metastasis are characteriZed by uncon
30

tumor groWth (Folkman, 1985).
Accordingly, the search for angiogenesis inhibitors Was
stimulated by the concept of “antiangiogenic therapy”. In its

simplest terms, antiangiogenic therapy sought a putative

The present invention provides a novel group of phos
phonic acid agents Which Were synthesiZed and character
iZed. This unique group of compounds are potent inhibitors
of angiogenesis, equipotent to 40 times greater than suramin.
In addition, results shoW that phosphonic acid agents dem
onstrate loWer toxicity and exert their antiangiogenic effect
via a different mechanism than suramin.

35

Without subscribing to any particular theory, it is believed
that phosphonic acid agents are potent inhibitors of angio
genesis and that the antiangiogenic effect is mediated
through a speci?c effect of these compounds upon prolifer
ating endothelial cells. The mechanism for inhibition of

40

angiogenesis by the phosphonic acid agents may involve
inhibition of DNA replication, cell signaling and/or energy

inhibitor of blood vessel groWth in the believe that such an

inhibitor might be therapeutic by limiting tumor groWth and
further such an inhibitor Would be non-toxic because angio

genesis is normally infrequent (Folkman, 1992). A number
of different factors can stimulate angiogenesis in vivo. These

only the preferred embodiments of the invention are shoWn
and described, simply by Way of illustration of the best mode
of carrying out the invention.
DESCRIPTION OF THE INVENTION

diabetic retinopathy, psoriasis, arthritis, hemangiomas and
trolled groWth of capillary blood vessels. The most striking
example of uncontrolled angiogenesis is associated With

The above and other objects of the invention Will become
readily apparent to those of skill in the relevant art from the

folloWing detailed description, tables and formulas, Wherein

hours (Denekamp, 1984).
HoWever, vascular endothelial cells undergo rapid prolif

of angiogenesis and tumorigenesis.
In parent application Ser. No. 08/889,996, the compounds
of the invention Were referred to as naphthylureas. HoWever,
the more appropriate class of the agents are as described
herein.

tumors do not groW beyond a siZe of 2—3 mm unless they are

able to stimulate the groWth of neW capillaries from the
existing vascular netWork. Additionally, the neW blood ves
sels provide an essential entry route to the vasculature for
metastasis of tumor cells. Cell division in endothelial cells
is sloW, With a turnover time of years rather than days or

In satisfaction of the foregoing objects and advantages,
the present invention provides phosphonic acid derivatives
of agents and methods for their preparation.
The invention also provides pharmaceutical compositions

angiogenic factors, such as basic ?broblast groWth factor

(bFGF), vascular endothelial groWth factor (VEGF),
platelet-derived groWth factor (PDGF) and transforming

production.

groWth factor 0t and [3, can be released from the tumor cells

groWth inhibiting activity of the phosphonic acid agents is

themselves and by other cells such as macrophages and

Furthermore, the antiangiogenic and endothelial cell
45

endothelial cells (Folkman, 1992).
The mechanisms by Which tumors induce angiogenesis
are very complex and involve many pathWays, an angio
genesis inhibitor could be directed against any of the com
ponents of the angiogenic cascade. The identi?cation of
compounds that block neovasculariZation has a long stand
ing interest. A number of inhibitory extracts have been

helial cell surface as has been demonstrated for suramin.

The ?ndings that this unique group of phosphonic acid
agents have more potent antiangiogenic activity, are less
toxic than suramin, and are metaboliZed and cleared in hours
rather than Weeks suggest that these agents are potent

therapeutic agents for “angiogenesis-dependent” diseases.

prepared from avascular tissues, such as cartilage (Braunhut
et al., 1989). One such method of treating tumors has been
by the administration of suramin. HoWever, it is believed
that suramin may have adverse effects in large dosages.
Accordingly, a continuing need exists for agents that
overcome the de?ciencies of prior antiangiogenic
compounds, including suramin. There is also a need for
antiangiogenic agents that have a reduced toxicity to a

55

60

inhibition of angiogenesis by the use of the phosphonic acid
agents to inhibit the groWth of various immortaliZed human
cancer cell lines. Further experiments provide in vivo mouse

toxicity studies and neurotoxicity in vitro assays.

origenesis.

Additionally, animal studies are presented in Which SCID or
nude mice are implanted With human tumors and then

SUMMARY OF THE INVENTION

positions containing said agents.

These diseases include diabetic retinopathy, arthritis,
psoriasis, tumor groWth and metastasis.
The commercial advantage of the phosphonic acid agents
resides is their loWer toxicity and enhanced antiangiogenic

activity. The experiments presented illustrate the potent

recipient and increase inhibition of angiogenesis and tum

It is an object of the present invention to provide novel
phosphonic acid substituted agents and pharmaceutical com

not primarily related to the inhibition of binding of the
angiogenic groWth factors to their receptors on the endot

65

treated With the selected phosphonic acid agents.

According to the present invention, phosphonic acid
agents, described by structural formula and chemical name,

6,160,166
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are potent inhibitors of angiogenesis and/or tumorigenesis

While exhibiting loW toxicity.
The present invention provides a preferred novel class of
phosphonic acid group substituted agents Which are de?ned

by the following formulae:

Wherein

10

P is a phosphonic group or a phosphonic salt, as for
example, a phosphonic group substituted With one or
more alkali metals;
15

R1 is H, CHZCOZH, or substituted or unsubstituted

alkyl;
R2 is substituted or unsubstituted alkyl, aryl, or aryla

lkyl;
Q1 and Q2 are substituted or unsubstituted aryl groups;

20

Y, P, n1, n2, m1, m2 R3 are as de?ned above;
R4 and R5 are independently H or a substituted or unsub

R3 is a substituted or unsubstituted aryl group;

stituted alkyl group;
R6 is H, or NCOR7; and
R7 is aryl, substituted aryl, or nitro substituted aryl.

25

j is 0, 1, or 2;
n1 and n2 are independently 0, 1, or 2; and
m1 and m2 are independently an integer from 1 to 4.

Preferred phosphonic acid agents of the invention are set

Embodiments of the phosphonic acid agents of the present
invention comprise compounds of the formulae:

forth beloW in Tables 1—3, Which tables provide chemical
formulae, molecular Weights, and properties of the com
pounds including some embryo and inhibition data.
TABLE 1

The code number, formula, molecular Weight, synthesis method, basic structure and substitutions
at positions 2, 3 and 4 for the phosphonic acid agents With small urea bridges are indicated.
H

2

Formula

Mol Wt Method

NE
NE
NE
NE
NE

158
161
473
426
392

C‘13H12N2O7P2Na2
C‘13H12N2O7P2Na2
CBHUNZOUPZNa2
CBHUNZOUPZNa2
CBHUNZOUPZNa2

416.2
416.2
504.2
504.2
504.2

B,
B,
G,
G,
G,

NE
NE
NE
NE

474
427
428
433

CUHMNZOUPZNa2
CBHMN4O9P2Na2
C‘15H14N4O9P2Na2
C21H22N4O13P2Li2

532.2
502.2
502.2
614.3

G, B, C, Fb
Fa, Fb, B, C
Fa, Fb, B, C
A, B, C

NE 434 C21H22N4O13P2Li2

614.3

C
C
B, C, Fb
B, C, Fb
B, C, Fb

CHZCOZH

2

N

3

T

3

O

4

Substitution at Position

#

%

—2

—3

—4

Em

Ih

H
H
OCOPO3HNa
H
H

PO3HNa
H
H
OCOPO3HNa
H

H
PO3HNa
H
H
OCOPO3HNa

23
21
20
22
24

H
H
H
H

CH3
NHCOPO3HNa
H
Al

OCOPO3HNa
H
NHCOPO3HNa
H

21

0
53
21
39
6
12

H

H

Al

Where Em represents Embryos; Ih: represents Inhibition; and Al is

—CONCH2PO3HLi

|

N

4

Synthesis
Code

H

I

6,160,166
TABLE 2
The code number, formula, molecular Weight, synthesis method, basic structure and substitutions
at positions 2, 3, 4, 4' and X for seven phosphonic acid agents With big urea bridges are indicated.

4

O

O

4

3

3

2

N

X

N

H

)L

H

T

T

H

Synthesis

Code

Formula

H

Substitution at Position

Mol Wt Method

2

#

%

Ih

3

4

X

Em

NF O69 C27H22N4O9P2Na2

654.4 A, B, C, D

PO3HNa

H

O

26

66

NF 681 C27H22N4O9P2Na2

654.4 A, B, C, D

H

PO3HNa

O

28

100

NF 162 C27H22N4O8P2SNa2

670.5 A, B, C, D

H

PO3HNa

S

4

O

O

3

N

2

N
4'

Synthesis

Method

N

3

T

H

4

O

N
4'

2

H

Substitution at Position

#

%

Ih

2

3

4

4'

Em

NF O68 C27H22N2O9P2Na2

654.4 A, B, C, D

H

PO3HNa

H

H

27

0

NF O67 C27H22N2O9P2Na2

654.4 A, B, C, D

H

H

PO3HNa

H

25

62

NF 540 C31H3UN4O9P2Na2

710.5 Ea, Ec, B, A, B, C

H

H

CH2PO3HNa CH3

NF 544 C33H38N4O15P4

854.6 Ea, Ec, B, A, B, C

CH2PO3H2

H

CH2PO3H2

CH3

TABLE 3
The code number, formula, molecular Weight, synthesis
method, and chemical structures of phosphonic acid agents are indicated.

Synthesis
Method
A

Compound

6,160,166
TABLE 3-continued
The code number, formula, molecular Weight, synthesis
method and chemical structures of phosphonic acid agents are indicated.

Synthesis
Method

Compound

A, B, C

N02

0

NH

H

H

N

N

O

NaHO3P

O Q PO3HNa

NF 167 C27H2ON4OUP2Na2 (684.40)

A, B, A,

B’ C

T‘
Na2O3P

O

N

T

O

f

f

N

N

O

T

H

T‘
N

T

O

H

PO3Na2

0

NF O50 CHH3DN6OUP2Na4 (936.62)

A, B, A,
B, C

NaHo3p\/@/

N

o

o

0

H

H

N

CH3

T
H

The syntheses of the phosphonic acid agents of this

45

\QVPO3HNa

T
H

cH3

from 698 to 855 depending on the substitutions at 2, 3, 4, 4‘
and X of the basic structures. The basic structures of this

group Were synthesized using synthetic methods A, B, C and
D indicated beloW. (See NF 067, 068, 069 and 681). NF 540
and NF 544 required synthetic steps Ea and Ec instead of D.
Table 3 shoWs four phosphonic acid agents With miscel

invention are shown in process Schemes 1 and 2 beloW.

General procedures for the syntheses are described under
Synthetic Methods A—G. Synthetic methods used for the
synthesis of the individual phosphonic acid agents are listed
in Tables 2—3.
The phosphonic acid agents synthesized herein can be
divided into three general groups. Table 1 shoWs phosphonic
acid agents With small urea bridges. The basic structural
formula, the chemical substitutions at each position, formula
and molecular Weight, are shoWn for each compound. The
molecular Weights of this group varied from 416 to 614
depending on the substitutions at positions 2, 3 and 4 of the

o

N

T
o

Synthesis of Phosphonic Acid Agents

N

laneous structures. Because of differences in the basic struc
tures of this group, the entire structure is shoWn With the

formula and molecular Weights. The molecular Weights of
this group varied from 424 to 949. NF 166 Was synthesized
55

basic structure. The basic structure of this group Was syn

thesized using synthetic methods B and C described beloW
(see structure for NF 158 and NF 161). Additional substi
tutions at positions 2, 3 and 4 Were made using synthetic
methods A, Fa, Fb and G as indicated in Table 1.
Table 2 shoWs seven phosphonic acid agents With large
urea bridges. TWo basic structural formulas With four ben

using synthetic method A described beloW. NF 167 required
synthetic method A, B and C, Whereas NF 050 and NF 542
required synthetic method A, B, A, B and C.
Schemes 1 and 2 as set forth beloW shoW general proce

dures for preparation of the novel compounds of this inven
tion. In Scheme 1, the phosphonic acid agents are prepared
by initial reduction of a nitro benzene phosphonic acid to the
amino derivative. This amino derivative is then reacted With
a di-acid halide to yield the phosphonic acid substituted

agent (e.g. compounds 4a, b). Such di-acid halides include

zene rings are shoWn With the chemical substitutions at each 65

phosgene, thiophosgene and a dicarboxylic acid halide sub
stituted aryl group.

position, formula and molecular Weights for each com
pound. The molecular Weights of this chemical group varied

In an alternative embodiment, the amino derivative is
reacted With a nitro benzoyl halide in a buffered medium and

6,160,166
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10

at temperatures of from about 20 to about 40° C. The
nitrobenZoyl halide is added in an organic solvent such as

on carbon to hydrogenate the nitro group and form an

aminobenZamido-benZenephosphonic acid.

toluene. At the conclusion of the reaction, the aqueous layer
and organic layer are separated and the aqueous layer is

The aminobenZamido-benZenephosphonic acid is then
dissolved in a buffered aqueous medium and treated With

acidi?ed by the addition of a mineral acid from Which a

phosgene in an organic solvent to produce the ?nal agent

precipitated intermediate product, nitrobenZamido
benZenephosphonic acid, is recovered.

precipitated product. These reactions are described more

speci?cally under Procedures A, B and C.
Scheme 1 General synthesis of the phosphonic acid
substituted agents:

This nitrobenZamido-benZenephosphonic acid is then
hydrogenated in the presence of a hydrogenation catalyst
comprising a precious metal such as palladium or platinum

Scheme 1

General synthesis of the phosphonic acid substituted agents:
0
0
H2031’

1

1'

I

H2031’

—NH2 +
/4

—NO; +
/4

3

3'

1

I

—N
/4 |
3

\
—4'N02

I

H

/
3,

2a, b

1
H2031’

1

1

\

/B\

| /—T
3

PO H

/

H2O3P

3 2

\

T—\ |

H

H

l0

1

1,

| /—T
4

3

3

\

I

H

INH;

/ 4
3,

4a, b

o

H2O3P

o

\

o

/1

|

—N

PO3H2

N—

|

I \

Biliid

Substitution pattern
a 1, 3

b 1, 4
c 1, 3

1

d 1, 3

1'

e 1, 4

1

f 1, 4

1

Scheme 2 sets forth a general synthesis for producing the

various arylalkyl-, phenoXycarbonyl-, and carbamoyl
phosphonic acid analogues. In these reactions, the substi
tuted benZene derivatives, compounds 11, 15 or 17 are
reacted With the appropriate alkyl phosphite to form com

pounds 13, 16 and 18, respectively. These compounds Will
contain the appropriate substituents as shoWn in Scheme 2.
65

More speci?cally, the chloromethyl substituted benZene
12 is reacted With an alkyl phosphite by heating at about 80°
C. up to re?ux for 3 to 10 hours. The resulting 12 is then
nitrated to 13. Compound 14 may then be produced from

6,160,166
11
compound 13 by heating With concentrated hydrochloric
acid and crystalliZing the product.

-continued
0

In a further embodiment, the nitrophenoXy carbonylchlo
ride 15 is reacted With an alkylphosphite in an exothermic 5

reaction to produce a nitrophenoXycarbonyl-phosphonic
acid dialkyl ester 16. This intermediate can be converted by

ON /
2

I

1

O

|I!/ocH3
\

OCH3 1) C1—Si(CH3)3

4 \

O

2) H2O, NaOH

16a-c

reaction With sodium iodide in a solvent With an haloalkyl

o

silane by heating at about 30° to about 50° C. to produce

compound 19.

10
1

/

Alternatively, the nitrophenylisocyanate (compound 17)

O2N—

is reacted With a dialkylphosphite in an eXothermic reaction

X

!/OH

\ONa

l

4 \

o

to yield the phosphonic acid ester (compound 18).
Thereafter, the phosphonic acid ester is reacted With triso
dium iodide in a solvent and With an halotrialkylsilane by
heating at about 30° to about 60° C. to produce compound
19. Compound 16 can be converted to compound 19 by the

19a-c X = O

15

20a, b X = NH
1

N=C=O

/

HOP(OCH3)2

O2N—

same procedure.

—>

4 \

Scheme 2 General synthesis of arylalkyl-,
17a, b

phenoXycarbonyl-carbamoyl-phosphonic acid agents
Scheme 2

General synthesis of arylalkyl—,
phenoXycarbonyl-carbamoyl-phosphonic acid agents

/

25

O2N—

l

H

0

IL

|I!/ocH3
\OCH3

l

4 \

Cl

0
18a, b

15-20
30

a: 4-NO2

b: 3-NO2
c: 2-NO2
11a R: H
11b R = cH2c1

Synthetic Methods for Phosphonic Acid Agents
35

A. 4-(4-NitrobenZamido)-benZenephosphonic
acid (3f)
4-AminobenZenephosphonic acid (1b) Was prepared as
described by Doak D. O. and Freedman C D,J. Amer. Chem.
40

Soc., 74, 753 (1952). Compound lb (17.3 g, 0.1 mol) Was
dissolved in 2 N NaOH (100 ml). To this solution (pH 8), a
solution of 4-nitrobenZoylchloride (2b, 30 g, 0.15 mol) in
toluene (100 ml) Was added dropWise at room temperature

45

With vigorous stirring. Stirring Was continued until no more
1b Was detectable by TLC. Soon after the beginning of the

addition of 4-nitrobenZoylchloride, 3f began to precipitate.
NaOH (2 N) Was added to the reaction mixture at a rate that

kept 3f in solution. At the end of the reaction, the aqueous
layer Was pH 11. The toluene layer Was separated. The
aqueous layer Was acidi?ed to pH 1.0 by addition of
concentrated hydrochloric acid and stirred for 30 min. The
precipitate Was ?ltrated and crystalliZed from methanol.

Yield 25.3 g (78%). Melting point: 257—260° C.
55

In a similar Way a series of aminoaryl- or aminoalkyl

phosphonic acids Was benZoylated using nitrobenZene-mono
or di-carbonylchlorides.

OZN
60
1

/ I

0

c1

B. 4-(4-AminobenZamido)-benZenephosphonic
acid (5f)
Compound 3f (8.05 g) Was dissolved in a mixture of 1 M

T P(OCH3)3

NaZCO3 (15 ml), Water (55 ml) and methanol (30 ml) (pH
8.0) and hydrogenated at room temperature at normal pres
65

sure using 10% Pd/C (200 mg) as catalyst. After absorption
of the theoretical amount of hydrogen (about 4 hr), the
?ltrate of the reaction miXture Was concentrated to 70 ml and

6,160,166
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14

acidi?ed With 2 N HCl to pH 6.0. The monosodium salt of
compound 5f precipitated. It Was Washed With Water and

of tWo drops of triethylamine led to a spontaneous exother
mic reaction. The reaction mixture Was crystalliZed from

dried at about 40° C. C13H13N2O4P (292.4);

methanol/ether yielding yelloW crystals (0.44 g, 32%), mp

C13H12N2O4PNa (314.4) monosodium salt of compound 5f.

1070 C. (3-nitrophenylcarbamoyl phosphonic acid

In a similar Way all aromatic nitro compounds used as
intermediates Were hydrogenated to the corresponding aro

dimethylester, 18b).

matic amino compounds.

Were dissolved in acetonitrile (30 ml). Chlorotrimethylsilane

b) Compound 18b (5 mmol) and sodium iodide (10 mmol)

C. 4,4‘-[Carbonylbis(imino-4,1

phenylencarbonylimino)]-bis-benZenephosphonic

10

acid (6f)
Compound 5f (5.85 g, 20) Was dissolved in Water (50 ml)
and 5 M NaOH (4.0 ml). To this solution, a 20% solution (2
M, 50 ml, 100 nmol) of phosgene in toluene Was added

dropWise (4 hr) under vigorous stirring. During the Whole

(15 mmol) Was added dropWise. The mixture Was heated to
about 40° C. for 30 min, cooled and ?ltrated. The ?ltrate Was
concentrated to a volume of 10 ml. Water (10 ml) Was added
and the pH of the solution Was adjusted to pH 3 by addition
of 0.1 N NaOH. The solution Was extracted three times With

ether (15 ml). The aqueous phase Was freeZe-dried, yielding
an amorphous poWder (20b).
15

G. 4-Nitrophenoxycarbonylphosphonic acid

reaction time, the pH of the reaction mixture Was maintained
at pH 5.0 by automatic addition of 5 M NaOH. Asuspension
Was formed during the addition of phosgene. The toluene
layer Was separated. The aqueous suspension Was acidi?ed
With 2 N HCl to pH 1 and stirred for 30 min. The precipitate
Was ?ltered by suction, stirred three times With Water (20 ml,

dimethylester (16a)
Trimethyl phosphite (4 ml, 30 mmol) Was added dropWise
under stirring and cooling to 4-nitrophenoxycarbonyl chlo
ride (15a, 6.4 g, 32 mmol) (exothermic reaction). The
reaction mixture Was crystalliZed from ether/pentane yield
ing yelloW crystals (16a, 6.8 g, 77%), mp 1050 C.

30 min) and dried.
Yield: 3.6 g (61%)

di-acid halide to yield the phosphonic acid substituted agent.

In a similar Way the 2-nitro- (16c) and 3-nitro- (16b)
analogues Were synthesiZed. (See also Doak G O and
Freedman C D. J. Amer Chem. Soc, 74:753, 1952. Kassack
M and Nickel P. J. Chromatogr. B, 686, 275—284, 1996,

A thiophosgene or a dicarboxylic acid halide Was used to

incorporated herein by reference in their entirety).

25

In a similar Way amino derivatives Were reacted With a

synthesiZe the corresponding agent.
D. Tetrasodium salt of compound 6f

30

Compound 3f (0.61 g 1.0 mol) Was suspended in Water
(10 ml). The suspension Was titrated very sloWly With 0.1 N
NaOH to pH 9.0. The resulting clear solution Was evapo
rated i. vacuum to dryness.

35

The basic structure of the molecules synthesiZed Were
similar to suramin. HoWever, the trisulfonic acid derivatives
Were replaced With phosphonic acid groups (PO3HNa) or

(—O—CO—PO3HNa) at the 2 (2‘), 3 (3‘) or 4 (4‘) positions.
These alterations resulted in loWer molecular Weights
(414—950) compared to the molecular Weight of suramin
(1429) and other trisulfonic acid analogues (1162—1541).
Both large urea and small urea phosphonic agents Were

synthesiZed. The chemical and pharmacological properties

TLC (Acetonitrile, NH3 conc., Water 6+2+2); compound
6f Rf 0.63; compound 5f Rf 0.75; compound 3f Rf 0.79;
4-NitrobenZoic acid Rf 0.75; HPLC purity of compound
6f>96% determined by the method described by Kassack
and Nickel (1996).

E. 4-Nitro-1,3-xylene-ot,ot-diphosphonic acid (14b)
a) 1,3-Bis-(chloromethyl)benZene (11b, 25 g, 0.1 mol)
and triethyl phosphite (36.5 g, 0.22 mol) Were heated under

are very different from those described for other suramin

analogues. The metabolic clearance rates of the phosphonic
40

EXAMPLE 1

Pharmacological Activities: Antiangiogenic Activity in the
45

re?ux for 10 hr.

b) The reaction mixture (12b, yelloW oil) Was cooled to

nitric acid (30 ml, 0.4 mol) and conc. sulfuric acid (30 ml)

angiogenesis, Was determined for suramin and each of the

at about 0—5° C. After 2 hr, the reaction mixture Was poured

phosphonic acid agents by measuring the ability of various

in ice Water (500 ml) and extracted With toluene. The toluene
extracts Were Washed With Water and evaporated, yielding a

yelloW oil (13b).
55

acid under re?ux for 20 hr. The reaction mixture Was

evaporated. The residue Was crystalliZed from Water yield

ing yelloW crystals of compound 14b (mp 1720 C., 15.8 g,
60

from 4-nitro-(x-chlorotoluene.

F. (3-Nitrophenyl)carbamoyl phosphonic acid
monosodium salt (20b)
a) 3-Nitrophenylisocyanate ((17b) 0.82 g, 5 mmol) and
dimethyl phosphite (0.55 g, 5 mmol) Were mixed. Addition

doses to inhibit angiogenesis in vivo in the chick egg
chorioallantoic membrane (CAM) assay as described by
Gagliardi et al. 1992. Some of the phosphonic acid agents
shoWed ID50 values signi?cantly loWer than suramin. TWo
phosphonic acid agents, NF 069 and NF 681, shoWed the
loWest ID50 values (4—8 times more active than suramin).

Six other phosphonic acid agents shoWed antiangiogenic

yield=50%).
In a similar Way using steps a) and c) (4-nitrophenyl)
methane phosphonic acid (14a) Was synthesiZed starting

Chick Chorioallantoic Membrane Assay In Vivo and the
Human Microvascular Endothelial Cells In Vitro
The purpose of this experiment Was to test the ability of

the phosphonic acid agents described above to inhibit angio
genesis. The ID50, the dose that produces 50% inhibition of

room temperature and added dropWise to a mixture of conc.

c) Compound 13b Was heated With conc. hydrochloric

acid agents appear to be much faster (hours versus 45—55

days for suramin).

65

activity that Was 2 to 4 times greater than suramin (NF 050,
NF 067, NF 161, NF 167 and NF 428). Other phosphonic
acid agents Were equipotent to suramin. These data clearly
indicate the discovery of a group of unique phosphonic acid
agents Which shoW antiangiogenic activity that is up to 8
fold greater than suramin in the CAM assay.
It Was also found that the compounds described above, in

general, shoWed a closely related antiangiogenic activity on
the groWth of human dermal Microvascular endothelial cells

6,160,166
15

16

stimulated by basic ?broblast growth factor (bFGF) in vitro.

While these studies shoWed that suramin is able to disrupt
the binding of groWth factors to their receptors in intact
cells, it also has diverse effects on other key enZymes

The IC50 values for those phosphonic acid agents Were
22—80 pM compared to 438 pM for suramin. This indicates

involved in signal transduction and mitogenesis that prob
ably contribute to its antiproliferative and antimetastatic

that these phosphonic acid agents are 5—40 times more

potent inhibitors of endothelial cell groWth than suramin in
vitro.

activities.
The data indicates that bFGF induced a dose-related
increase in total protein and total DNA in human dermal

EXAMPLE 2
10

microvascular and porcine pulmonary artery endothelial
cells. The presence of suramin (210 pM) inhibited the
stimulatory effect of bFGF, as has also been reported by
Takano et al. (1994) and Braddock et al. (1994) for bovine

esis in the CAM is completed by day 11. Measurements of

aorta and bovine adrenal microvascular endothelial cells. In

intercapillary distances are also consistent With the cessation
15

the presence of much loWer concentrations (25 pM), the
phosphonic agents, NF 050, NF 067, NF 069, NF 681, NF
161, NF 167 and NF 428, not only inhibited the stimulation
of endothelial cell groWth by bFGF but signi?cantly reduced

Differences in the Effect of Suramin and the Phosphonic
Acid Agents on Angiogenesis in the 6-Day Old and 11-Day
Old CAM Assay

According to Ausprunk et al. (1974), capillary angiogen
of capillary groWth after day 10. Flamme et al. (1991)
shoWed that CAM ?uid contains angiogenic groWth factors,
that the mitogenic activity of these groWth factors Was
temporally related to the vascular groWth in the CAM, and
that by day 10, there Was a sharp decrease in groWth factor
activity in the CAM ?uid Which preceded the termination of
capillary groWth by one day. Based on these observations,

total protein content far beloW the unstimulated control
endothelial cells. These exciting results shoW that the agents
are much more potent inhibitors of endothelial cell groWth

than suramin and that mechanisms other than blocking
groWth factor binding to endothelial cells play a very

the effect of suramin and some phosphonic acid agents on
the established vessels of the CAM membrane after cessa
tion of vascular groWth Was determined. The implants Were

prepared as previously described by Gagliardi et al. (1992),
implanted on day 11 and read on day 13.
The results of this study shoWed that the phosphonic acid

important role in their antiangiogenic activity.
The results With suramin are similar to those reported in
25

agents (NF 067, NF 069, NF 681) Were very potent inhibi
tors of angiogenesis in the 6-day CAM and exhibited no

signi?cant inhibitory activity in the 11 day CAM (see Table
4). Suramin shoWed antiangiogenic activity in both the
6-day and 11-day CAMs.

CAM (6-day) but do not affect the established vasculature

that suramin inhibited I125 bFGF binding in a dose-related
manner. HoWever, the phosphonic agents in the same molar
concentrations used for suramin did not affect either the total
or the speci?c binding of the iodinated groWth factor to the
endothelial cells. The percentage of inhibition of I125 bFGF

binding to loW and high af?nity binding sites of human
microvascular endothelial cells Was 96% at 70 pM of

suramin, decreasing to 9% at 25 pM of suramin. HoWever,

This is a very important ?nding and suggests that the
phosphonic acid agents are very potent inhibitors of angio

genesis during the phase of rapidly groWing vessels in the

the literature (Takano et al., 1994 and Braddock et al., 1994)

35

(11-day CAM). On the other hand, suramin clearly affected

for the same concentrations of the phosphonic acid agents,
the inhibition of groWth factor binding Was alWays less than
5% in relation to the control. These data clearly shoW that We
have identi?ed a chemical group that are very potent as

antiangiogenic agents and express their activity through

both the groWing and established vascular cells. These
results indicate that the mechanisms of action of suramin
and the phosphonic acid agents on angiogenesis are differ
ent. Additional experiments compare the mechanisms of
actions of the phosphonic acid agents on angiogenesis in

different mechanisms than those Widely accepted for
suramin.
As described above, the phosphonic acid agents are very

inhibitory in the actively groWing vessels of the 6-day CAM
but shoWed almost no activity on the established vessels of

v1vo.

TABLE 4

45

Comparison of the inhibition of angiogenesis by 70 nmol of
surarnin or a equimolar amount of a phosphonic acid agents in the

6-dav and 11-day chick egg chorioallantoic (CAM assay.

Analogues
surarnin
NF O68
NF O67
NF O69
NF 681

Chemical

6-day CAM

Structure

% Inhibition

11-day CAM
% Inhibition

64
O
63
68
100

50
0
0
0
0

phosphonic
phosphonic
phosphonic
phosphonic

groWth, the phosphonic acid agents are 10-fold more inhibi
tory for groWing cultures than for con?uent human
microvascular endothelial cell cultures.
This in vitro ?nding corroborates our data With the CAM
assay in different phases of groWth, suggesting that this neW

class of phosphonic acid agents target groWing blood ves
sels.
EXAMPLE 4
55

Differences in the GroWth Inhibitory Effects of Suramin and
the Phosphonic Acid Agents in Human Microvascular
Endothelial Cells and Established Cancer Cell Lines in
Culture

We have investigated the activity of the phosphonic acid

EXAMPLE 3

Differences in the Inhibitory Effects of Suramin and the
Phosphonic Acid Agents on bFGF-Stimulated and Non
Stimulated Endothelial Cells
Suramin is a highly charged molecule With six sulfonate
groups that are ioniZed at physiologic pH. This results in

agents on some tumor cell lines proliferation in vitro and

compared this activity With the antiangiogenic activity of

signi?cant nonspeci?c binding to polypeptide groWth fac
tors (Coffey et al., 1987). HoWever, suramin also exhibits
speci?city by binding to speci?c sites on a groWth factor,
similar to heparin binding to bFGF (Middaugh et al., 1992).

the 11-day CAM (see Table 2). When compared With the
MTT assay con?uent and loW density cultures in log phase

65

these compounds in the CAM assay and their inhibitory
activity in human microvascular endothelial cell groWth.
The MTT assay (Carmichael et al., 1987) Was used to
examine the effects of suramin and selected phosphonic acid
agents on cell proliferation. Suramin and the phosphonic
acid agents inhibited cell proliferation in a dose-related
manner. Analysis of the inhibitory action of the phosphonic

6,160,166
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18

acid agents in adrenal cortex carcinoma (SW13), human

renal tubular epithelium. The animals treated With equimolar
doses of the phosphonic analogues shoWed no signi?cant

pancreatic adenocarcinoma (CFPAK- 1), human prostate car
cinomas (LNCap and PC3) shoWed IC50 equipotent or

changes in any important pathologic microscopic ?ndings in

values less than suramin. In other cell lines, such as human

those tissue samples.
These studies clearly indicate that the phosphonic acid
agents shoW signi?cantly loWer toxicity than suramin and its
trisulfonic acid analogs.

breast carcinomas (MCF7 and T47D), human ?brosarcoma
(HT1080), human colon adenocarcinoma (CaCo2), human

glioblastoma (U87), kidney carcinoma (A498) and lung
carcinoma (A427), the phosphonic acid agents shoWed IC50
values higher than suramin.
The phosphonic acid agents, NF 067 (Which is 20 times
more potent than suramin in inhibiting microvascular endot

EXAMPLE 6
10

the Chick Chorioallantoic Membrane Assay
The phosphonic acid agents are extremely potent antian
giogenic compounds With molecular Weights that are about

helial cell groWth), expressed very loW antiproliferative
activity against different cancer cell lines in vitro. Our data
and the reports in the literature strengthen our important
?nding that some of the phosphonic acid agents are more
potent inhibitors of angiogenesis in the CAM assay and to
human microvascular endothelial cell groWth than suramin.

Structure-activity Relationship for the Antiangiogenic
Activity of the Phosphonic Acid Agents GroWing Vessels in

15

half that of suramin. The phosphonic acid agents are up to
30 times more active than suramin in the CAM assay.

Furthermore, the nonspeci?c binding of these compounds to

This effect is not observed With some cancer cell lines. This

serum proteins is loWer than suramin and probably, as a

suggests that there is speci?city for endothelial cells in the
inhibitory effect of the phosphonic acid agents not observed
With suramin and the other trisulfonic acid analogues.

consequence, a higher proportion is available in the free
form to the cells and the half life is shorter. The siZe of the

20

EXAMPLE 5

The Toxicity of Suramin and the Phosphonic Acid Agents in
vivo in Mice
A limitation on the clinical use of suramin is the narroW 25

margin betWeen the dose required to achieve anti-tumor
activity and that leading to the onset of prohibitive toxic side
effects. Suramin toxicity has been revieWed by LaRocca et
al. (1990). It is clear that compounds With similar antitumor
activity to suramin but With substantially loWer toxicity

30

Would be of considerable potential therapeutic value as an

antitumorigenic or antiangiogenic agent. Toxicity studies
Were performed With suramin, three sulfonic analogues
35

phonic agents (10 to 40 times more potent). Mice Were

injected intraperitoneally With 0—150 pM/kg body Weight of
the compounds to be tested, every other day for a total of ?ve
injections. The animals Were carefully observed daily and
Weighed every third day for 28 days after the last injection.
After the 28-day observation period, the animals Were
euthaniZed, blood Was collected through cardiac puncture
and the folloWing tissues Were subjected to histological

molecular Weights (650—900) (see Table 2). Athird group of
four phosphonic acid agents With miscellaneous structures is
shoWn in Table 3.
There is considerable variation in antiangiogenic activity
in compounds of similar structure. For example, NE 068,
Which is structurally very similar to NE 067, NE 069 and NE
681 (all are phosphonic acid agents With the same molecular
Weight), shoWed a substantial difference in the antiangio

concentration of NE 069 and NE 681 (90% inhibition). This
suggests that slight steric modi?cations in the molecule can
induce dramatic changes in the potency of inhibition of
angiogenesis, opening neW avenues for antiangiogenic drugs

design.
40

EXAMPLE 7

The Structure Activity Relationship for Inhibition of bFGF
Induced Cell GroWth in Human Microvascular Endothelial
Cells

investigation: heart, lungs, liver, spleen, adrenal gland,
kidney, sciatic nerve, soleus muscle and brain.
Animals treated With suramin at the highest dose (150

acid agents have molecular Weights of less than 600 and
contained small central urea bridges (see Table 1), shoWed
less antiangiogenic activity than the seven phosphonic acid
agents Which have big central urea bridges and higher

genic activity (0% inhibition) in comparison With the same

more potent (2 times) than suramin in relation to inhibition

of angiogenesis and endothelial cell groWth and four phos

molecule also appeared important. Ten of the phosphonic

Dose response curves Were determined for the most active
45

agents in human microvascular endothelial cell cultures
treated With various concentrations in the presence or

pM/kg body Weight) died before completion of the ?ve
injections. We observed poor coat condition, Weight loss,

absence of bFGF. Inhibition of cell groWth Was evaluated by
measuring total protein and total DNA and the IC50 Was

eye irritation and lacrimation by the end of the ?ve injections

estimated for each dose response curve. The most potent

in animals treated With suramin. The poor coat condition and

compounds in relation to the inhibition of bFGF-induced
endothelial cell groWth Were the phosphonic acid agents.

reduction of 10—15% in body Weight occurred at 150, 75 and

35 pM/kg body Weight during the injection period. The coats

Our results shoW a close correlation betWeen the inhibi

and eye irritation became better but not normal and the body
Weight stabiliZed but did not return to normal over the

subsequent 28 days of observation. A similar response Was

55

seen in tWo of the three sulfonic acid analogues that Were
tested. On the other hand, no mice treated With the four

phosphonic acid agents died during the acute injection
phase. Furthermore, their body Weight did not decrease but
they continued to gain Weight at the same rate as the control
animals at all levels of treatment. The body coat Was normal
and no eye irritation Was noted in all animals treated With

60

phosphonic acid agents With signi?cantly loWer molecular
Weight, less charged and much higher antiangiogenic activ

phosphonic acid agents.
Histological analysis of the tissues from animals treated
With suramin shoWed a dose-related frequency of lipoid
degeneration of the Zona reticularis of the adrenal gland and
vacuolar changes in the proximal convoluted tubules of the

tion of angiogenesis in vivo and the inhibition of endothelial
cell stimulated groWth in culture for the selected agents.
Among the ?ve most active agents in vitro, four Were
phosphonic acid agents, the same compounds Which Were
the most antiangiogenic in the CAM assay. These results
suggest that the inhibition of angiogenesis in vivo in the
CAM assay may involve a speci?c suppression of endothe
lial cell groWth. Thus, We have identi?ed a speci?c group of

ity than suramin and its sulfonic acid analogs.
The ?nding that a unique chemical group of the phos
65

phonic acid agents, are much more potent as antiangiogenic

compounds, less toxic and With shorter half-lifes than
suramin, suggest that the phosphonic acid agents are of

6,160,166
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clinical signi?cance and Widen the therapeutic WindoW for
treatment of angiogenic dependent diseases.

vitro and compared this activity With the antiangiogenic
activity of these compounds in the CAM assay and their
inhibitory activity in human microvascular endothelial cell
groWth. The MTT assay (Carmichael et al., 1987) Was used

EXAMPLE 8

Differences in the Inhibitory Effects of Suramin and the
Phosphonic Acid Agents to bFGF-stimulated and Non
stimulated Endothelial Cells
Suramin is a highly charged molecule With six sulfonate
groups that are ioniZed at physiologic pH. This results in

to examine the effects of suramin and selected phosphonic
acid analogues on cell proliferation. Suramin and the phos
phonic acid agents inhibited cell proliferation in a dose
related manner. Analysis of the inhibitory action of suramin
and the phosphonic acid agents in adrenal cortex carcinoma

signi?cant nonspeci?c binding to polypeptide groWth fac

(SW13), human pancreatic adenocarcinoma (CFPAK-1),

tors (Coffey et al., 1987). HoWever, suramin also exhibits a
degree of speci?city by binding to speci?c sites on a groWth
factor, similar to heparin binding to bFGF (Middaugh et al.,
1992). While these studies shoWed that suramin is able to
disrupt the binding of groWth factors to their receptors in
intact cells, it has diverse effects on other key enZymes

10

involved in signal transduction and mitogenesis that prob
ably contribute to its antiproliferative and antimetastatic

15

?brosarcoma (HT1080), human colon adenocarcinoma

related increase in total protein and total DNA in human

dermal microvascular and porcine pulmonary artery endot
20

The presence of suramin (210 pM) inhibited the groWth
factor stimulatory effect, as has also been reported by
Takano et al. (1992) and Braddock et al. (1994) for bovine

there is speci?city for endothelial cells in the antiangiogenic
effect of the phosphonic acid agents.
25

and the Phosphonic Acid Agents in vivo in Mice
A limitation on the clinical use of suramin is the narroW
30

and high af?nity binding sites of human microvascular

groWth and the four most active phosphonic analogues (up

trations of phosphonic acid agents, the inhibition of groWth
45

ture and the folloWing tissues Were kept for histological

investigation: heart, lungs, liver, spleen, adrenal gland,

through different mechanisms than those Widely accepted

kidney, sciatic nerve, soleus muscle and brain.
Animals treated With suramin at the highest dose (150

for suramin.
The phosphonic acid agents are very inhibitory in the

pM/Kg body Weight) died before completion of the ?ve
injections. Poor coat condition, Weight loss, eye irritation

actively groWing vessels of the 6-day CAM but shoWed
almost no activity on the established vessels of the 11-day
CAM. When compared With the MTT assay con?uent and

and lacrimation Was observed by the end of the ?ve injec
tions in animals treated With suramin. The poor coat con

loW density cultures in log phase groWth, the phosphonic
55
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EXAMPLE 9

We have compared the activity of suramin and the phos
phonic acid agents on some tumor cell lines proliferation in

dition and reduction of 10—15% in body Weight occurred at

150, 75 and 35 pM/Kg body Weight during the injection
period. The coat condition and eye irritation became better
but not normal and the body Weight stabiliZed but did not
return to normal over the subsequent 28 days of observation.
On the other hand, mice treated With the phosphonic acid

CAM assay in different phases of groWth, suggesting that
this neW class of suramin analogues target groWing blood

Differences in the GroWth Inhibitory Effects of Suramin and
the Phosphonic Acid Analogues in Human Microvascular
Endothelial Cells and Established Cancer Cell Lines in
Culture

suramin or equimolar doses of the sulfonated analogues or

the phosphonic analogues or the phosphonic acid agents
(1—150 pM/Kg body Weight) every other day for a total of
?ve injections. The animals Were carefully observed daily
and Weighed every third day for 28 days after the last
injection. After the 28-day observation period, the animals
Were euthaniZed, blood Was collected through cardiac punc

potent as antiangiogenic agents that express their activity

vessels and does not effect established blood vessels.

liminary toxicity studies Were performed With suramin, three
sulfonic analogues more potent (2 times) than suramin in
to 30 times). Mice Were injected intraperitoneally With

40

endothelial cells Was 96% at 70 pM of suramin, decreasing

acid agents are 10-fold more inhibitory for groWing cultures
than for con?uent human microvascular endothelial cell
cultures. This in vitro ?nding corroborates our data With the

value as an antitumorigenic or antiangiogenic agent. Pre

relation to inhibition of angiogenesis and endothelial cell

to 9% at 25 pM of suramin. HoWever, for the same concen

factor binding Was alWays less than 5% in relation to the
control. These data clearly shoW that there is identi?ed a
chemical group of phosphonic acid agents that are very

margin betWeen the dose required to achieve anti-tumor
activity and that leading to the onset of prohibitive toxic side
effects. Suramin toxicity has been revieWed by LaRocca et
al. (1990). It is clear from studies so far that compounds With
equipotent or greater antitumor activity but With substan

tially loWer toxicity are of considerable potential therapeutic
35

the same molar concentrations used for suramin did not

affect either the total or the speci?c binding of the iodinated
groWth factor to the endothelial cells.
The percentage of inhibition of I125 bFGF binding to loW

EXAMPLE 10

Comparative Toxicity of Suramin, Trisulfonic Analogues

unstimulated control endothelial cells.
These results shoW that the phosphonic acid agents are

much more potent than suramin in inhibiting angiogenesis
and that mechanisms other than blocking groWth factor
binding to endothelial cells play a very important role in
their antiangiogenic activity. Results With suramin are simi
lar to those reported in the literature (Takano et al., 1992 and
Braddock et al., 1994) that suramin inhibited bFGF binding
in a dose-related manner; but the phosphonic analogues in

phosphonic acid agents are much more potent inhibitors of
angiogenesis in the CAM assay and to human microvascular
endothelial cell groWth than suramin. This effect is not
observed With some cancer cell lines. This suggests that

aorta and bovine adrenal microvascular endothelial cells. In

the presence of much loWer concentrations (25 pM), the
phosphonic agents, NF 067, NF 069 and NF 681, not only
inhibited the stimulation of endothelial cell groWth by bFGF
but signi?cantly reduced total protein content far beloW the

(CaCo2), human glioblastoma (U87), kidney carcinoma
(A498) and lung carcinoma (A427), the phosphonic acid
agents shoWed equipotent or loWer inhibitory activity in
comparison to suramin.
Our data strengthened our important ?nding that the

activities. Our data shoWed that bFGF induced a dose

helial cells.

human prostate carcinomas (LNCap and PC3) shoWed IC50
value equipotent or less than suramin. In other cell lines,
such as human breast carcinomas (MCF7 and T47D), human

agents did not die during the acute injection phase.
Furthermore, their body Weight did not decrease but they
continued to gain Weight at the same rate as the control
animals at all levels of treatment. The body coat Was normal
and no eye irritation Was noted.
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Histological analysis of the tissues from animals treated
With suramin shoWed a dose-related frequency of lipoid
degeneration of the Zona reticularis of the adrenal gland and

6,160,166
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vacuolar changes in the proximal convoluted tubules of the
renal tubular epithelium. The animals treated With equimolar
doses of the phosphonic acid agents shoWed no signi?cant

macrovascular endothelial cell groWth. As a matter of fact,
a stimulatory effect on cell groWth With suramin at 50—100
pig/ml Was detected. HoWever, at concentrations higher than
250 pig/ml, there Was a signi?cant dose-related reduction in

changes in any important pathologic microscopic ?ndings in
those tissue samples. These preliminary studies clearly indi
cate that the phosphonic acid agents shoW a greater than

total protein and total DNA. The phosphonic acid agents
alWays shoWed potent reduction in total protein and total

10-fold increase in antiangiogenic activity and signi?cantly
loWer toxicity.

DNA even at loWer concentrations, suggesting, once again,
a different and speci?c mode of action on endothelial cells

EXAMPLE 11

Structure of Phosphonic Acid Agents

by the agents.
10

endothelial cell groWth in vitro, availability, chemical purity
and sampling of each different chemical structure subgroup.

15

TWenty-tWo phosphonic acid agents, including NF 067, NF
068 NF 069, NF 681, and NF 162, synthesiZed by our
laboratory, are used in various concentrations. In the CAM
assay, the ID50 for suramin Was 75 nmol and the ID50 for

the phosphonic acid agents, NF 069, NF 681 and NF 067,

20

Was respectively, 9, 2 and 32 nmol. The estimated IC50 for
suramin in the bFGF-stimulated human microvascular
endothelial cells Was 437 pM and for NF 069, NF 681 and

NF 067 Were respectively, 75, 1.5 and 19.4 pM, re?ecting
activity that is up to 200 times more potent than suramin. NF

25

068 is a closely related compound chemically Which does
not shoW any antiangiogenic activity. The structures of these
phosphonic acid agents and suramin are shoWn in Tables
1—3.
The inventors have identi?ed a clear correlation betWeen

EXAMPLE 13

The Time Course for Inhibition of Protein Synthesis by the
Phosphonic Acid Agents in Human Microvascular Endot

The phosphonic acid agents studied Were selected based
on the criteria of drug potency in relation to inhibition of
angiogenesis in the CAM and inhibition of microvascular

helial Cells
3H-Leucine incorporation is used to determine the effect
of the phosphonic acid agents and suramin on protein
synthesis in HMEC-1 and HMVEC-d cells. HMEC-1 or
HMVEC-d cells are groWn to con?uence in ?asks (P100)
and IC50 doses of the phosphonic analogues or suramin are
added for time periods of 6 to 36 hr. For each time period,
siX replicate ?asks are set up. The volume of the medium
MCDB-131 is 10 ml per ?ask. After incubation, the medium
Was replaced With fresh MCDB-131 containing 0.37 MB ml
of 3H-leucine and incubated for a further 90 min. TritonX
100 (240 pl, 10%) Were then added to the contents of each

?ask and agitated. Trichloroacetic acid (TCA) (4 ml, 20%)
is added, the contents miXed and the ?asks left overnight at
room temperature. After 24 hr, the ?ask contents Was

suspended by shaking, transferred to tubes and centrifuged
30

at 4300 g. The pellets Were resuspended in 10% TCA and
recentrifuged and then resuspended in 3.0 ml of 0.1 M

the chemical structure and antiangiogenic activity. The phos

NaOH. Half of this volume Was transferred to scintillation

phonic acid agents are far more potent inhibitors of angio

vials in 10 ml of Emulsi?er Safe scintillation ?uid (Packard)
While the remaining 1.5 ml Was used to assay DNA content
(LaBarca and Paigen, 1980). The radioactive counts due to
protein synthesiZed in the presence of 3H-leucine Was nor
maliZed to counts/pg DNA. Protein synthesis by cells treated
With the phosphonic acid agents are expressed relative to
that of control cells as the percent of inhibition for each time
of incubation.

genesis and bFGF-stimulated endothelial cell groWth than
any suramin. Furthermore, the phosphonic acid analogues
With large central urea bridges are in general more active
than the group With small central bridges or other con?gu
rations.
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EXAMPLE 12

Effects of the Phosphonic Acid Agents and Suramin on DNA
Synthesis and Human Microvascular Endothelial Cell
GroWth

40

phonic acid agents Was used as a measure of the inhibition

3H-Thymidine incorporation is used to determine the

of protein synthesis. There Was no change in the rate of

effect of the phosphonic acid agents and suramin on DNA

synthesis in HMEC-1 and HMVEC-d cells. Logarithmically

45

groWing HMEC-1 or HMVEC-d cells are seeded at 2><104

cells/Well in siX Well plates (Falcon) containing 2 ml of

pM) and equimolar concentrations of the phosphonic acid

for 24 hr. 3H-Thymidine (ICN Radiochemicals) is added and
incorporation alloWed to proceed for an additional 30 min.
After removal of medium, the cell layer is Washed tWice

EXAMPLE 14

Determination of the Sensitive Phase of the Cell Cycle for
55

Suramin has been shoWn to inhibit cell cycle progression
at different phases in various cancer cell lines. There is no
60

GF/C) and the radioactivity is determined in a liquid scin

tillation spectrometer (Packard).
The effect of various concentrations of suramin and the

data available on the effect of the phosphonic acid agents
and suramin on cell cycle in human microvascular endot
helial cells. Jindal et al. (1990) ?rst described the inhibitory
action of suramin on DNA synthesis and proposed that it Was
due to a direct action on cellular DNA polymerases. Data

phosphonic acid agents on cell groWth and ongoing DNA

inhibitory effect on HMEC-1 and porcine pulmonary artery

the Inhibitory Effects of the Phosphonic Acid Agents and
Suramin on Human Microvascular Endothelial Cells

phosphate-buffered saline, and then 1 ml of cold 10%

synthesis is measured. The inventors found that concentra
tions of suramin up to 100 pig/ml did not have any signi?cant

incubated together for at least 24 hr. It Was shoWn that this
is the time necessary for a reasonable amount of suramin to

signi?cant after a short time of incubation because these
compounds are smaller and less charged than suramin.

agents are added to different Wells, and the plates incubated

trichloroacetic acid are added. Acid precipitable radioactiv
ity are collected on a glass ?ber ?lter (Whatman Grade

protein synthesis until suramin and the cells have been

be taken up by HMEC-1 cells (Gagliardi et al., 1996). After
this period of time, the rate steadily declines. The inhibition
of protein synthesis by the phosphonic acid agents Was

MCDB-131 medium supplemented With 5% fetal bovine
serum (FBS) (Hyclone). Various amounts of suramin (0—500

With 1 ml of cold Hanks balanced salt solution and the cells
are dislodged by trypsiniZation. The cells are collected in
microcentrifuge tubes and Washed tWice With 1 ml of cold

Comparison of 3H-leucine incorporation into cellular pro
tein in the presence or absence of suramin and the phos

65

from in vitro studies suggest that the optimal bene?t from
suramin may require prolonged eXposure time. It has been
reported that prostate carcinoma cells, treated in vitro With
suramin, are sloWly arrested in the G1 phase. Cell arrest in
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the G1 phase became evident only after 24 hr of exposure
and suramin also induced a decrease in cells in the S phase

attachment, spreading and migration of human endothelial
cells (Yamamura et al., 1996). The distribution of PKC
isotypes is cell speci?c. The discovery of these isotypes that
have distinct physiologic functions provides an explanation

(Qiao et al., 1994). Suramin inhibited proliferation of human
cerebral meningioma cells and increased the percentage of
cells in the S and G2/M phase of the cell cycle. As suramin
simultaneously decreased the proliferation rate shoWn by

for the plethora of cellular events that are mediated by PKC.

Investigation of PKC isotypes in human umbilical vein
macrovascular endothelial cell (HUVEC) With Northern and
Western blot analyses demonstrated the presence of PKC

direct cell counting and 3H-thymidine uptake, the effect in
the G2/M phase cannot be attributed to increased prolifera

tive activity.

alpha, delta, epsilon, eta, theta and Zeta (Haller et al., 1996).

Consequently, suramin must lead to a prolongation of the
S and G2/M phases or to an arrest during these cell cycle

10

phases. HoWever, the data shoWed that the human microvas

markedly doWn regulated after prolonged treatment With
phorbol esters (Yamamura et al., 1996).

cular endothelial cells are much more sensitive to inhibition

by both suramin and the phosphonic acid agents than the

large vessel endothelium, suggesting a stronger promoting

15

activity of bFGF on microvascular as opposed to macrovas

cular endothelial cells, as described by Braddock et al.

(1994).
EXAMPLE 15
Effects of the Phosphonic Acid Agents on the Transit Time

20

of Endothelial Cells Through the Cell Cycle
Experiments using ?oW cytometry are performed to deter
mine the effects of the phosphonic acid agents at different
doses and comparing them to the results With suramin.
HMEC-1 and HMVEC-d synchroniZed cells are used to
analyZe the effects of selected phosphonic acid agents on the
distribution of cells in the various phases of the cell cycle

using the propidium iodide method according to Vindelov et
al. (1985). Brie?y, 104 cells are seeded With MCDB-131.
After 24 hr, the medium is replaced With fresh medium
containing the test compounds at 0—500 pM. After exposure
times of 12, 24, 48 and 72 hr, the cells are collected by

25

the MCDB-131 culture medium containing 5% FBS, cells
30

35

(10—200 ng/ml), and the inactive analogue, 4-ot-PDD
inhibitor for PKC, RO-318220, is also used in a similar
manner as the control. After the indicated time points, the
cells are Washed With cold PBS and PKC is assayed With
(Ac-MBP(4-14)), Which acts as speci?c substrate of PKC

EXAMPLE 16
45

on the Inhibition of Human Microvascular Endothelial Cell

(Koide et al., 1992). To each Well, 100 pl total volume of the
folloWing are added: lysis buffer (?nal concentration: 0.137

mM NaCl, 5.4 pM KCl, 0.3 pM Na3PO4, 0.4 pM K2HPO4,
1 mg/ml glucose, 20 miM HEPES, 10 mM MgCl2, 50 pig/ml
digitonin and 25 mM B-glycerophosphate, pH 7.2), 100 pM
(gamma32P) ATP, 2.3 mM CaCl2, 2pg/ml
phosphatidylserine, and 100 pM Ac-MBP. After incubation,

GroWth by the Phosphonic Acid Agents
Many studies have unraveled the importance of cell
signaling pathWays in the inhibitory action of certain com
pounds. Protein kinase C (PKC) is involved in apoptosis
induction by some compounds, and suramin has been shoWn
to inhibit PKC. Suramin inhibits PKC type I—III activity in

50 pl from each Well are spotted onto phosphocellulose
disks, Washed With 1% concentrated H3PO4 in Water, and

a concentration-dependent manner With an ID50=50 pM.

The inhibition of cyclic AMP-dependent protein kinase
activity Was much less sensitive to suramin With an IC50= 55

656 pM (Mahoney et al., 1990). Similar inhibitory effects
Were observed With M-kinase, the constitutively active cata

counted. Results are expressed as the percentage of inhibi
tion in comparison to cultures treated With bFGF or active

phorbol esters.
The phosphonic acid agents shoW a strong inhibitory
effect on PKC activity and this effect can be counter bal

lytic fragment of PKC, and autophosphorylation of PKC
60

anced by the addition of active phorbol esters. A clear
inhibition of PKCa, the isotype that seems to play the most
important role in endothelial cells.
EXAMPLE 18

important regulatory elements in signal transduction, cellu

activation of PKC is both necessary and sufficient for

are Washed With MCDB-131 only and then incubated With
the experimental media. Several experiments are necessary
to understand the role of the phosphonic acid agents on
PKC. Con?uent cells are treated With bFGF (10 ng/ml) in
the presence or absence of suramin (100, 200, 400 and 800
pig/ml) or equimolar concentrations of the phosphonic acid
agents for 5—10—30—60 and 120 minutes. Con?uent cultures
are treated With the active phorbol esters, PMA and PDD

(Montesano and Orci, 1985) in the presence or absence of
suramin or selected phosphonic acid analogues. A speci?c

involved in the inhibition of endothelial cell groWth by
phosphonic acid agents and suramin.

lar regulation and tumor promotion. It has been shoWn that
endothelial cell proliferation in response to bFGF is depen
dent upon activation of PKC (Kent et al., 1995) and that

Effects of the Phosphonic Acid Agents on PKC Activity, in
situ, in Human Microvascular Endothelial Cells in Culture
HMEC-1 or HMVEC-d cultures are groWn to con?uence

results enable us to understand if the same mechanisms are

types I—III.
PKC consists of a family of gene products in animal
tissues composed of at least ten distinct proteins (alpha, beta,
gamma, delta, epsilon, eta, theta, Zeta, iota and mu) that are

suggest that PKC alpha and epsilon are the isotypes involved
With cytoskeleton events, endothelial cell migration and the
proliferative response to bFGF. Because of the importance
of PKC in regulating pleiotropic biological processes, it is of
importance to identify the inhibition of PKC by the phos
phonic analogues in endothelial cells.

on gelatiniZed 96-Well plates. After a 24-hr incubation With

These studies compare the effects of the phosphonic acid
agents on the percentage of cells in different phases of the
cycle for human microvascular endothelial cells. These

Determination of the Involvement of Cell Signaling Path
Way Components, Protein Kinase C and p34CDC2 Kinase,

The doWn regulation of PKC alpha and epsilon inhibited
endothelial cell migration and proliferation. These ?ndings

EXAMPLE 17

trypsiniZation, stained With propidium iodide and analyZed
by ?oW cytometry for the percentage of cells in G0/G1, S,
and G2/M phase.

Endothelial cell stimulation by bFGF has been Well docu
mented to increase cytosolic and perinuclear PKC alpha and
epsilon immunoreactivity. These same PKC isotypes Were

PKC Isotypes Involved in Induction of Apoptosis in
65

Microvascular Endothelial Cells
Several experiments are necessary to understand Which

isotypes of PKC respond to cell groWth and apoptosis. The
expression of different PKC isotypes are determined in

6,160,166
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subcon?uent cultures, con?uent quiescent cultures, subcon

trifugation and extensive Washing With hypotonic buffer.

?uent cultures treated With bFGF or VEGF, subcon?uent

The nuclei are incubated for 30 min in the presence of 350

cultures treated With each of the phosphonic acid agents and

(10—200 ng/ml), PMA and PDD and the inactive analog, 4

mM NaCl and the nonsoluble nuclear material removed by
ultracentrifugation (20 min at 40000 rpm in TL 100 Beck
man ultracentrifuge). The protein concentration are adjusted
to 1.5 mg/ml, 20% of glycerol are added and the extracts

a-PDD (control) (Montesano and Orci, 1985). HMEC-1 and

stored at —20° C.

subcon?uent cultures treated With bFGF or VEGF. Subcon
?uent cultures are also treated With the active phorbol esters

p13-agarose precipitation: extracts (300 pg protein) or
puri?ed p34cdc2 kinase (50 ng protein) are diluted in 400 pl

HMVEC-d cells are also treated With the phorbol esters in
the presence or absence of the various phosphonic acid

analogues. A speci?c inhibitor for PKC, RO-318220, are

10

of precipitation buffer in the presence and absence of

phonic acid analogues (Tsopanoglou, 1994).

suramin (0—20—120 pM) or the phosphonic acid agents in
equimolar concentrations. After 10 min, 15 pl of p13

The total RNA is extracted and the mRNA for the speci?c
isotypes is determined by Northern blots as described by
Mattila et al. (1994). The protein for each speci?c PKC

agarose are added and samples incubated at 4° C. for 1—3 hr.
The samples are subjected to a brief centrifugation, the
supernatant eliminated and the precipitates are Washed four

also used in a similar manner With and Without the phos

isotype is separated and determined by Western blot analysis

15

tates are used immediately for kinase assays or Western blot.

in dishes treated in the same fashion as described above.

Cells are analyZed for apoptosis as described.

The conventional PKC isotypes (alpha, beta, gamma) are
calcium and phospholipid dependent Whereas the novel
isotypes (delta, epsilon, eta and theta) do not require calcium

20

for activation. Zeta is both calcium and phorbol ester inde

pendent. The isotypes have not been reported in any human
microvascular endothelial cells. HoWever, for the rat mac

rovascular and human macrovascular cells, only alpha and
epsilon appear to be involved in groWth. The experiments

25

their inhibition by phosphonic acid analogues When treated

(Beckman).

Western blot: the precipitates are electrophoresed in

12.5% 12x12 cm ready-made polyacrylamide gels (Daichi
30

immobiliZed antigens are revealed using bitinylated second
ary antibodies With biotinyl-tyramide/streptavidin reagent

microvascular endothelial cells.
35

Effects of the Phosphonic Acid Agents on p34CDC2 Kinase
Activity in Human Microvascular Endothelial Cells in Cul

master DTS chromoscan are used for band quanti?cation

(BojanoWski et al., 1994).
40

interruption and G2 block (Boj anoWski et al., 1994). In

increase the global tyrosine speci?c phosphorylation of
cellular proteins in vivo and the ?rst suramin-sensitive
45

the absence or presence of estradiol or insulin-like groWth

and Miller, 1993). The Western blot shoWs different elec
treated or not treated With suramin and the phosphonic acid

accumulation of MCF-7 human breast cancer cells in the
50

has a direct inhibitory effect on puri?ed cdc2 kinase and also

modulates the tyrosine phosphorylation of cdc2 kinase in
extracts from human small cell lung cancer cells, suggesting
that suramin might have a double inhibitory effect on cdc2
kinase in vivo: one blocking the kinase activity and the

tyrosine phosphatase has recently been described (Ghosh
trophoretic mobility p34cdc2 kinase bands betWeen samples

factor-1. Prolonged exposure (48 hr) to suramin caused an

G2-M phase of the cell cycle (Foekens et al., 1993). Suramin

Suramin inhibits p34cdc2 kinase activity in a dose-related
manner and the phosphonic acid agents are also potent

p34cdc2 kinase inhibitors. Suramin has been reported to

studies using DNA ?oW cytometry, suramin inhibited men

ingioma cell proliferation in ?ve different tumor lines by
arresting cells in G2-M and S phases of the cell cycle
(Schrell et al., 1995). These effects Were found under
serum-containing and serum-free culture conditions, and in

(Blast kit, Dupont, USA) to increase the sensitivity of the
signal and NitrotetraZolium/NADH substrate (POD kit,
WAKO, Japan) to visualiZe it. A Pharmacia LKB image

ture

CDC2 kinase is the key enZyme controlling G2-M tran
sition in human cells and its inactivation results in cell cycle

Co.) and the proteins transferred to Immobilon PVDF mem
branes (Millipore). Nonspeci?c binding sites on the mem
branes are saturated With 5% skim milk in PBS. The

With phorbol esters. This Would suggest that PKC is a major
pathWay for the induction of apoptosis in the human
EXAMPLE 19

p34cdc2 kinase assay: 25 ng of puri?ed p34cdc2 kinase or
p-13 agarose precipitates are incubated in 20 pl of kinase
buffer, 32P-ATP and p34cdc2 kinase substrate, With or
Without suramin and the phosphonic acid agents at 25° C. for
20 min. Reactions are stopped by placing the samples on ice
and spotting 5 pl of the reaction mixture onto P81 phospho
cellulose ?lters (Whatman). Filters are Washed three times in
50 mM phosphoric acid, dried and the radioactivity retained
on the ?lters are determined by liquid scintillation

shoW Which PKC isotypes are stimulated by phorbol esters
or are inhibited by the phosphonic acid analogues. A major
goal is to determine if these PKC isotypes can overcome

times in precipitation buffer With vortexing and transferred
to a clean Eppendorf tube after the third Wash. The precipi

(Mattila et al., 1994). The measure of apoptosis is carried out

agents, and the immunoblot With anti-phosphotyrosine anti
body exhibits a difference in p34cdc2 kinase tyrosine phos

phorylation.
EXAMPLE 20

Programmed Cell Death (Apoptosis) Induced by Phospho
55

nic Acid Agents in Human Microvascular Endothelial Cells
To measure the induction of apoptosis by the phosphonic

second, protecting the tyrosine phosphorylation of the

acid agents, quiescent and exponentially groWing endothe

enZyme. CDC kinase Was found to be important in cell
proliferation, and suramin Was reported to in?uence this
60

lial cells are analyZed. After 24 hr of seeding (loW cell
density) or after con?uence is reached (high cell density),
the medium is changed With fresh medium containing vari
ous amounts of the phosphonic acid agents. The experiments

kinase as Well.

The effects of selected phosphonic acid agents on the
p34cdc2-related kinase activity are carried out essentially as

With con?uent cultures are carried out also in the presence

described by BojanoWski et al. (1994).
Cytoplasmic and nuclear extractions: 100 million cells
(HMVEC-1 or HMEC-d) are Washed tWice With cold PBS
and incubated in hypotonic phosphate buffer for 45 min on
ice. The cells are then disrupted With a Dounce homogeniZer
and nuclei separated from the cytoplasmic fraction by cen

65

or absence of bFGF (10 ng/ml). After various exposure times
(6—36 hr), the cells are harvested and analyZed for the
induction of apoptosis by four different methods:
a) The cells are ?xed With 70% ethanol, spread onto
microscope slides, stained With acridine orange and ana

lyZed for nuclei (500 cells counted per data point).
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CAM assay. To explore the possibility that suramin and/or
the phosphonic acid agents induce apoptosis in vascular
cells, 6-day old chick embryos are treated With suramin or

b) The cells are ?xed in 4% buffered formalin, air dried

onto lysine coated slides, quenched for endogenous peroxi
dases With 2% hydrogen peroxide, treated With terminal

the phosphonic acid agents (0—200 pM) and injected in the
CAM ?uid (in the 6-day CAM, the angiogenic vessels groW

deoxyribonucleotide triphosphatase, folloWed by anti
dioxigenin-peroxidase, DAB substrate solution and ?nally,
methyl green. Cells (100) are counted to determine the

rapidly embedded With CAM ?uid). After 24, 48 and 72 hr

percentage of Apotag-positive cells per data point.

of treatment With the compounds or saline as control, the
CAMs are resected for DNA isolation and analysis for

c) To demonstrate DNA fragmentation (DNA laddering),

oligonucleosomal fragmentation as previously described by

harvested cells are treated With protease k and sodium

dodecyl sulfate for 12 hr to degrade cellular protein. The
DNA are extracted With phenol/chloroform/isoamyl alcohol,
folloWed by ethanol precipitation. The air dried DNA pellet

10

phosphonic acid agents, cryostat sections prepared from
CAMs treated for 24—48 and 72 hr are examined for apop

is re-suspended in TE buffer and run on a 1% agarose gel for
2 hr at 120 volts. The gels are stained With ethidium bromide

and photographed.

15

d) To determine the time course of events more exactly
and to discover Whether the cells enter apoptosis from the
G0/G1 stage or S/M stages, a neW ?oW cytometry method
established in our Flow Cytometry Core Facility based on
the method of Reid et al. (1996) is used. The harvested cells
are stained With Hoechst 33342 and merocyanine 540,

Brooks et al., (1994). To identify those cells Within the CAM
undergoing apoptosis in response to the treatment With the

tosis by the Apo-Tag immunoreactivity kit and for endot
helial cell speci?c staining. Co-localiZation of these markers
in the same cells demonstrate that inhibition of angiogenesis

by the phosphonic acid agents in vivo in the 6-day CAM
assay involves induction of programmed cell death of
microvascular endothelial cells.
20

EXAMPLE 23

Inhibition Effects of Phosphonic Acid Agents on Integrins

analyZed by How cytometry and divided in ?ve groups:

and Human Microvascular Endothelial Cell Adhesion

viable G0/G1, viable s/G2/M, early apoptotic G0/G1, early
apoptotic S/G2/M, and fragmented DNA (late apoptotic)

identi?ed as a marker of angiogenic blood vessels in the

cells.

The adhesion receptor integrin, otv[33, has recently been

The phosphonic acid agents induce programmed cell

chick chorioallantoic membrane and in humans (Brooks et
al. 1994). It Was also apparent that this integrin played a very

death in human microvascular endothelial cells that are

important role in angiogenesis. Topical application of a

actively proliferating and that the apoptosis process is trig
gered by cell detachment.

blood vessels in the chick CAM in response to cytokines and

25

EXAMPLE 21

speci?c antibody against otv[33 prevented the groWth of neW
30

human microvascular endothelial cells in culture and that

suramin is probably transported by the caveolae system. The
suramin incorporation by HMEC-1 cells increased and

related to induction of cell proliferation, motility, gene

expression and programmed cell death (Ruoslahti and Reed,
35

40

ably play an important role in the functions and survival of

ml of MCDB-131 Without FBS) obtained from Moravek
Biochemicals (Brea, Calif.) Was incubated at 37° C. in 5%

COZ/air for different periods of time (2—72 hr). Triplicates

45

differentiation has occurred and mature blood vessels

Different cell fractions Were transferred to separate scintil

formed, integrin otv[33 signaling is no longer required for
50

Counter.

The phosphonic acid analogues are taken up by HMEC-1
and HMVEC-d cells much faster and in higher amounts than
suramin because the phosphonic acid agents are smaller, less
charged molecules than suramin and less bound to proteins.
The demonstration that the phosphonic acid agents can reach
signi?cant intracellular concentrations and its localiZation is
very important for the understanding of the mechanism of

action of these compounds.

survival of the microvascular endothelial cells and they
become refractory to the deleterious effects of the speci?c

integrin antagonists. In conclusion, antagonists of integrin
otv[33 disrupt neWly forming blood vessels Without affecting
the preexisting vasculature (Brooks et al., 1994).
55

We observed that cultures of human microvascular endot
helial cells treated With suramin and more clearly With the

phosphonic acid agents shoWed a large number of ?oating
cells after 24 hr of treatment. Similar ?ndings Were reported
60

EXAMPLE 22

Effects of Phosphonic Acid Agents on Programmed Cell
Death in the Chick Chorioallantoic Membrane (CAM)

by Pepper et al. (1994) With bovine microvascular endothe
lial cells treated With suramin, and by Mitchen et al. (1993)
With primary epithelial cell cultures from human prostate
treated With suramin. When endothelial cells are cultured

The CAM assay has been reported as a suitable model for

the demonstration of “in vivo” induced apoptosis (Brooks et
al., 1994). We have shoWn that suramin and the phosphonic
acid agents are potent inhibitors of angiogenesis in the 6-day

microvascular endothelial cells undergoing angiogenesis.
It has been shoWn that prevention of ligation of the otv[33
integrin to the extracellular matrix promotes apoptosis of
microvascular endothelial cells Which have been induced by
angiogenic groWth factors to enter the cell cycle. After

each incubation period, the cells Were processed through
different Washings and ?nally to differential centrifugation.
lation vials, solubiliZed in a liquid scintillation cocktail and
counted in a 2000 CA TRICARB Liquid Scintillation

shape and motility of endothelial cells on the extracellular

matrix. These signaling events triggered by integrins prob

and HMVEC-d cells. Brie?y, tritiated suramin (13 pCi/100

Were carried out for each period of incubation. At the end of

1994; Meredith et al., 1993). In fact, recent studies have
shoWn that ligation of otv[33 on human endothelial cells in
vitro promotes a rise in calcium and pH (Leavesley et al.,

1993), activation of focal adhesion kinase (De?llipi et al.,
1994) and the polymeriZation of the actin cytoskeleton
(Sastry and HorWitZ, 1993), Which in turn regulates cellular

reached a plateau around 24 hr of incubation, and more than
50% of the suramin taken up by HMEC-1 cells Went to the

nucleus. Our group is synthesiZing various tritiated phos
phonic acid agents that are used for experiments in HMEC-1

fragments of tumors (Brooks et al., 1994). In vitro, cell
interaction With extracellular matrix has been shoWn to be

Uptake and Intracellular Distribution of 3H-phosphonic
Acid Analogues by Human Microvascular Endothelial Cells
We have already shoWn that 3H-suramin is taken up by

65

under conditions that prevent adhesion and spreading, they
stop groWing, become detached, acquire a round cell shape
and enter programmed cell death (Re et al., 1994).
The regulation of integrin function by the urokinase

receptor has also been reported (Wei et al., 1996), suggesting
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that reagents that affect the urokinase receptor can alter

et al., 1994). These methods Were established in our labo

integrin function by disrupting the urokinase plasminogen
receptor-integrin association representing potential thera

ratory and used to study the effect of tamoxifen (a partial
antiestrogen) on proteolytic properties of human microvas

peutic agents for tumor invasion and progression. The
speci?c inhibition of the activity of the urokinase receptor
mediated cell surface plasminogen activation system by

cular endothelial cells. These same methods are used to

determine the effects of phosphonic acid agents.
Human microvascular endothelial cells (HMEC-1 and
HMVEC-d) are plated in 96 Well culture plates. After 24 hr,
the medium are replaced With fresh MCDB-131 containing
5% FCS and varying amounts of the phosphonic acid agents.

suramin and the direct effect of suramin on the cell surface

associated With the urokinase receptor has already been

shoWn (Behrendt et al., 1993; Ellis and Dano, 1993; Pepper
et al., 1994). We postulate that the phosphonic acid agents
might interfere With microvascular endothelial cell adhesion
to the extracellular matrix, altering integrin functions, caus
ing endothelial cell detachment and consequential induction

10

5% COZ/air, the cells are Washed and lysed. Total protein is
determined in the lysate and 1 pg of total protein is used to
determine plasminogen activator (PA) activity With a chro

of apoptosis.
Cell attachment assay: The effects of the phosphonic acid
agents in variable amounts (0—200 pM) on the interaction of
human microvascular endothelial cells With components of
the extracellular matrix, such as laminin (interacts With

The experiment is carried out in the presence or absence of
10 ng/ml bFGF. After 18—24 hr of incubation at 37° C. With

15

mogenic method (American Diagnostica, CT) and With a
microplate reader. Human urokinase (Calbiochem, La Jolla,
Calif.) is used to generate the standard curve of PA activity.
Results are expressed as the percentage of control activity.

integrin (x261), ?bronectin (interacts With integrin (x561)

Zymographic analysis of PA is performed according to the

and vitronectin (interacts With integrin otv[33), are studied as

method of Granelli et al. (1983).
The phosphonic acid agents express inhibitory activity on
the proteolytic properties in a dose-related manner.

described by Sriramarao et al. (1993). Brie?y, different
concentrations of the proteins (0—10 pig/ml) diluted in PBS

20

are immobiliZed on 96 Well plates by incubating overnight

EXAMPLE 25
Effect of the Phosphonic Acid Agents on Cell Matrix Matal

at 4° C. The unbound sites are then blocked With serum free

medium (MCDB-131 containing 1% BSA and 10 mM
HEPES) by incubating the Wells for 1 hr at 37° C. The

25

loproteinases (MMPs) in the Endothelial Cells

30

enZymes responsible for the degradation of the extracellular
matrix components, such as collagen and proteoglycans.
Currently, 16 family members have been identi?ed. MMP
family member differ from each other structurally by the

Matrix metalloproteinases are an important group of Zinc

human microvascular endothelial cells are harvested after

Washing With PBS and incubating the cells With a PBS
based free enZyme free cell dissociation solution for 30 min
at 37° C. The cell suspension are Washed With free serum

medium and resuspended at 5><104 cells/ml and 100 pl are

presence or absence of domains that contribute to activities

added to each Well. The plates are incubated for 1 hr at 37°

such as substrate speci?city, inhibitor binding, matrix bind

C. For the anti-integrin antibody (used as positive control),
the cells are preincubated for 30 min before being added to
the protein coated Wells. Plates are Washed tWice With PBS
containing 1 mM calcium and magnesium to remove
unbound cells. The adherent cells are ?xed With 3.5%

ing and cell surface localization (PoWell and Matrisian,
35

paraformaldehyde containing 0.5% crystal violet. Endothe

raphy. Tissue samples Were placed in glass homogeniZers in

lial cells are gently Washed and adherent cells quantitated by
measuring the absorbance at 595 nm on a microtiter plate

reader.
Human microvascular endothelial cells treated With the
active phosphonic acid agents shoW a decrease in the
percentage of cells attached in relation to the controls. This
effect is dose-related. Furthermore, We expect to see more

signi?cant changes When the plates are coated With vitronec
tin because its interaction With integrin otv[33 is inhibited by

40

immediately analyZed by Zymography. Protein content of
45

each sample Was determined by a modi?ed LoWry method.
MMP enZyme activity Was detected using polyacrylamide

gel eltrophoresis Zymography. SDS-polyacrylamide gel
electrophoresis (PAGE) Was performed using 8% acryla
mide gels containing 0.1% gelatin. The volume of test

for the detection of any suramin toxicity on endothelial cells
even at concentrations higher than 200 pM. Hence, any
effect observed in this short time incubation experiment can
be interpreted as solely due to inhibition of cell attachment
to the extracellular matrix by the phosphonic acid agents.

samples loaded Was 15 pl. Electrophoresis Was run at 4° C.

at a constant voltage (100 volts). After electrophoresis, gels
Were incubated in Triton X-100 (2.5%) for 30 minutes to

EXAMPLE 24
55

eliminate SDS, prior to being incubated overnight in 50 mM
Tris HCL, pH7.5, containing 10 mM CaCl2 at 37° C. The
gels Were stained in 0.25% (W/v) Coomassie Brilliant Blue
and destained in methanol:acetic acid:Water (50:40:10). The
clear Zones in these gels indicates the presence of proteins

A tightly controlled increase in extracellular proteolysis,

With gelatinolytic activity. This method alloWs for identi?
cation of pro-metalloproteinases. Migration position of pro
teins and With standard molecular Weight and supernatant

restricted both in time and space, is a very important
component of the angiogenic process. This has led to the

notion that compounds capable of inhibiting proteolysis

a three fold Weight/volume of lysis buffer consisting of 50
mM Tris-HCL, pH=7.4, With 200 mM sodium chloride and
0.1% Triton X-100. The samples Were homogeniZed and
centrifuged at 1500 g for 20 min. The supernatant Was

polyanions (Panetti et al., 1995). It takes longer than 12 hr

Effects of the Phosphonic Acid Agents on the Production of
Protease by Human Microvascular Endothelial Cells in vitro

1996). To determine if the phosphonic acid agents Were
effective inhibitors of the MMP’s of endothelial cells, cells
Were incubated in the presence of the different agents for 48
hours. Tissue samples Were taken and subjected to Zymog

60

from HT 1080 cells that express MMP-2 and MMP-9 Were

could be effective in inhibiting angiogenesis (Pepper et al.,
1994). Indeed, protease inhibitors do inhibit angiogenesis

used as controls.

and suramin has been shoWn to alter the proteolytic prop
erties of bovine microvascular endothelial cells. Suramin
has been shoWn to signi?cantly inhibit plasminogen activa
tor activity induced by bFGF in fetal bovine aortic endot

are as folloWs: NE 050, NE 162 and NE 681 are potent

helial cells at concentrations higher than 250 pig/ml (Takano

The results With human microvascular endothelial cells

65

inhibitors of MMP-2 activity. bFGF increased MMP-2 activ
ity in human microvacular endothelial cells and these phos
phonic acid agents inhibited the increase in MMP-2 activity
induced by bFGF. These results suggest that the MMP-2 in

6,160,166
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endothelial cells may be an important component in the

ferent agents for 48 hours. Tissue samples Were taken and

angiogenesis process. This inhibition of MMP-2 by the
phosphonic acid agents may be an important mechanism for
the inhibition of angiogenesis.

subjected to Zymography. Tissue samples Were placed in
glass homogeniZers in a three fold Weight/volume of lysis
buffer consisting of 50 mM Tris-HCL, pH=7.4, With 200

EXAMPLE 26

mM sodium chloride and 0.1% Triton X-100. The samples
Were homogeniZed and centrifuged at 1500 g for 20 minutes.

Effect of the Phosphonic Acid Agents on Cell Matrix Met

The supernatant Was immediately analyZed by Zymography.

alloproteinases (MMP’s) in Cancer Cells in vitro

Protein content of each sample Was determined by a modi

For a tumor cell to metastasiZe, it must break aWay from

its neighbors and penetrate through the surrounding stoma
and the basement membrane to enter the circulation. The

10

extensive degradation of the extracellular matrix component
in tumor cells depends on the secretion of a battery of

metalloendopeptidases that digest a Wide range of proteins

of the extracellular matrix (Woessner, 1991).
Several recent reports have shoWn a correlation betWeen
MMP expression and tumor invasiveness in prostate cancer.
Pajough et al. (1991) found that MMP-7 Was increased in

malignant compared to benign prostatic tissue but absent in
the stroma. Boag and Young (1993) found increased levels
of gelatinase A (MMP-2) in malignant prostate and meta
static tissue. Stearns and Wang (1993) analyZed prostrate
cancer tissue extracts for gelatinase A (MMP-2) using
Northern blot studies. Their results suggested that the

15

graded series of ethanol. FroZen sections can also be uti

liZed. The endogenous peroxidase is eliminated by incuba
tion in 3% hydrogen peroxide for 30 minutes, and nonspe
ci?c binding of IgG to tissue protein blocked by incubation
With 100% normal rabbit serum for 1 hour. The sections are
20

then reacted With monoclonal anti-human gelatinase A
(MMP-2) or B (MMP-9) antibody raised in mouse

(Oncogene Research Products, 4° C. overnight. Biotinylated

enZyme is selectively overexpressed by malignant preinva
sive epithelial cells With very loW levels in benign tissue and
the stroma surrounding the tumor. Wilson et al. (1993)

?ed LoWry method.
The expression of metalloproteinases 2 and 9 and tissue
inhibitors of metalloproteinases (TIMP) 1 and 2 in human
prostate tumor xenografts in nude mice is determined by the
indirect immunoperoxidase method. Brie?y, tissue sections
are deparaf?niZed by 100% xylene and then hydrated With a

25

anti-mouse antibody is used as the secondary antibody
folloWed by peroxidase-strepavidin complex. The slides are
rinsed three times With PBS after each tetrahydrochloride
and hematoxylin used for nuclear staining. Negative con

reported gelatinolytic proteinase activities in human prostate

trols omitting either the primary or secondary antibodies are

secretions, With an increased level of expression in neoplas

used for nonspeci?c staining. The ratio (%) of immunore

tic compared to benign disease. The results presented by
Hamdy et al. (1994) suggest that MMP-9 activity is
increased in malignant compared to benign prostatic tissue.
The gelatinase B (MMP-9) Was not expressed in benign

active cells to total carcinoma cells is measured by counting
30

Immunohistochemistry detection kit (Oncogene Research

tissue but Was detected in 42% of prostate carcinomas.
Furthermore, those Who exhibited MMP-9 activity in vitro

had particularly unfavorable clinical parameters, including

Products, Cambridge, Mass.).
35

Well-established prognostic factors, such as high Gleason

Migration in vitro
Suramin inhibits multiple control points of angiogenesis,
40

metastasis and are major functional contributors to the
metastatic process. MMP’s are important contributors to the

cells is a key step in the angiogenesis process and appears to
45

are susceptible to inhibition by the general serum proteinase

inhibitor, ot-2-macroglobulin, and by a family of speci?c

cell migration than suramin (10 to 30 times).
EXAMPLE 28
55

Effect of the Phosphonic Acid Agents on Tube Formation in
Endothelial Cells in vitro
Endothelial cell differentiation on Matrigel is a useful in

vitro model for the study of certain steps in angiogenesis

above, We have shoWn that the agents are potent inhibitors

(Schnaper et al., 1993). The possibility that the phosphonic
60

acid agents inhibit angiogenesis in vitro has been studied
using Matrigel, a reconstituted matrix prepared from the
Englebreth-Holm-SWarm (EHS) tumor extracellular matrix
(Kleinman et al., 1982). When human umbilical vein endot
helial cells or bovine microvascular endothelial cells Were

treatment.

To determine if the phosphonic acid agents Were effective
inhibitors of the MMP’s of prostate cancer cells (PC3 and
DU-145), cells Were incubated in the presence of the dif

cell proliferation (Takano et al., 1994). Suramin signi?cantly

acid agents are much more potent inhibitors of endothelial

active MMP. TIMP-1 is associated With progelatinase B and

of MMP-9 activity in prostate cancer cells (PC-3) cells.
MMP-2 activity is inhibited in DU-145 prostate cancer cell
lines in vitro by the agents. This ?nding that the agents are
potent inhibitors of MMP’s activity clearly indicates an
important neW therapeutic function for the agents in cancer

be more sensitive to suramin inhibition than does endothelial

inhibited endothelial cell migration determined by both the
number of cells that migrated and the distance traveled by
the cells from the Wound edge. The data con?rmed that
suramin inhibits microvascular endothelial cell migration in
concentrations above 150 pig/ml and that the phosphonic

tissue inhibitors of metalloproteinases (TIMP). The tWo
major members of this family, TIMP-1 and TIMP-2, are
expressed by a variety of cell types. They form non
covalent, stoichiometric complexes With both latent and
TIMP-2 is associated With progelatinase A. Malignant
tumors many times exhibit complex patterns of expression
of MMP’s and TIMP’s and therapeutic intervention might
induce changes in this balance.
Using the in vitro protocol described in EXAMPLE 25

such as angiogenic groWth factors binding to endothelial cell

surface, endothelial cell migration, proliferation and produc
tion of proteases (Coffey et al., 1987, Braddock et al., 1994,
Pepper et al., 1994). Migration of microvascular endothelial

initial groWth of metastasis, regulating access to groWth
factors from the extracellular matrix and increasing angio

genesis (Chambers and Matrisian, 1997). Activated MMP’s

EXAMPLE 27

Effect of the Phosphonic Acid Agents on Endothelial Cell

scores, serum PSA levels and primary tumor ploidy.

Furthermore, 100% of the patients that did not respond to
treatment expressed MMP-9.
Metalloproteinases have long been associated With

cells in ?ve different ?elds at X200. TlMPS’s 1 and 2 are
detected in froZen sections of the tumors using a monoclonal
mouse antibody for human TIMP’s and the Mouse Unitect

65

seeded onto Matrigel, they formed a netWork of capillary
like structures, mimicking the steps that occur during the
formation of neW microvessels. Thus, the culture of endot

6,160,166
33

34

helial cells on Matrigel serves as a useful model for the study

section of the peritoneal lining for support, typically the
overlying skin. The Drabkin method (Drabkin reagent kit
525, Sigma, St Louis, M0.) is used to measure hemoglobin

of endothelial cell activity during in vitro angiogenesis.
Although there is a dramatic morphologic change in
endothelial cell population involving cell elongation, anas
tomosis and branching, gene transcription and translation
are not required for the regulation of this process (Zimrin et

al., 1995). Rather, post-translation-al events are involved
since the Matrigel-dependent process could be inhibited by
addition of a protein kinase inhibitor.
To measure the effect of the phosphonic acid agents on the

ability of tube formation by human microvascular endothe
lial cells, 200 pl of Matrigel is plated on a 24 Well culture
plates. After the Matrigel is alloWed to gel for 30 min at 37°
C., 40,000 cells (previously groWn on plastic dishes) in 1 ml
MCDB-131 medium is plated onto the Matrigel. After 18
and 24 hr, the cultures are ?xed, stained and the area of tubes
formed on the surface of the Matrigel are quantitated using

10

is used.
The model described by Passaniti et al. (1992) is used as

it gives ready quantitative assessment of angiogenesis and is
15

an image analysis system (Loats Associates, Inc.,

al. (1992). Furthermore, the active phosphonic acid agents
angiogenesis. Moreover, a direct correlation is found
betWeen the potency of inhibition of angiogenesis in the

ng/ml) to determine if the inhibitory effect of the phosphonic
acid agents can be overcome by the stimulation of PKC With
a phorbol ester.
The phosphonic acid agents inhibit tube formation in a

CAM assay and in the mouse model for the phosphonic acid

analogues.
EXAMPLE 30
25

The compounds of the present invention are useful in

pharmaceutical compositions for systemic administration to

EXAMPLE 29

humans and animals in unit dosage forms, such as tablets,

Antiangiogenic Effects of the Phosphonic Acid Agents

capsules, pills, poWders, granules, suppositories, sterile

Expressed in an in vivo Mammalian (Mouse) Model of

parenteral solutions or suspensions, sterile non-parenteral
30

The phosphonic acid agents inhibit angiogenesis in a
simple and rapid in vivo model that alloWs the ready

solutions or suspensions oral solutions or suspensions, oil in
Water or Water in oil emulsions and the like, containing

suitable quantities of an active ingredient. Topical applica
tion can be in the form of ointments, creams, lotions, jellies,

quantitative assessment of angiogenic and antiangiogenic
factors. The method developed by Passaniti et al. (1992)
consists of subcutaneously injecting mice With bFGF
embedded in Matrigel in the presence of heparin. Subcuta
neous injection of Matrigel plus bFGF and heparin at the
ventral midline achieved optimal and reproducible
responses. Sprouts from vessels in the adjacent tissue pen
etrated the gel Within 2 days, connecting it With the external
vasculature and reaching a plateau after 4 days, and persisted
up to 8 days. Matrigel forms a solid gel When injected into
mice and support a rapid and intense angiogenic reaction in
the presence of heparin and bFGF. Matrigel has been used to
promote differentiation of endothelial cells into capillary

reliable and shoWn to be useful in testing biological factors
and drugs that regulate angiogenesis. Suramin is an effective
inhibitor of angiogenesis in vivo as described by Pesenti et
are 10 to 30 times more active than suramin in inhibiting

ried out in the presence of various amounts of PMA (40—200

Angiogenesis

measure the total area of neovessels, a computeriZed

digitalyZer, the Optomax image analysis system (Optomax),

Westminster, Md). Additional experiments need to be car

dose-dependent manner and that stimulation of PKC by the
phorbol ester might overcome the inhibition.

levels in the implants. Protein content of the supernatant
?uid is determined using the BioRad protein assay method.
All specimens are ?xed in 10% buffered formalin for at least
24 hr, dehydrated, embedded in paraf?n and sectioned at 5
micron thickness, deparaf?niZed, and stained With hema
toxylin and eosin. Selected sections are stained for Factor
VIII-related antigen using an immunoperoxidase method. To

35

sprays, douches, and the like. For oral administration either
solid or ?uid unit dosage forms can be prepared With the
compounds of Formula I. The compounds are useful in

pharmaceutical compositions (Wt %) of the active ingredient
With a carrier or vehicle in the composition in about 1 to 20%
40

and preferably about 5 to 15%.
Either ?uid or solid unit dosage forms can be readily
prepared for oral administration. For example, the com
pounds can be mixed With conventional ingredients such as

dicalciumphosphate, magnesium aluminum silicate, magne
sium stearate, calcium sulfate, starch, talc, lactose, acacia,
45

methyl cellulose and functionally similar materials as phar

structures in culture, and When utiliZed as a vehicle in vivo,

maceutical excipients or carriers. A sustained release for

may enhance the selectivity of endothelial cells entering the
gel since basement membranes are not readily crossed by
?broblasts and other cells. Gels supplemented With bFGF
and heparin induced intense vasculariZation. The site of
injection and the age of the mice can affect the magnitude of

mulation may optionally be used. Capsules may be formu
lated by mixing the compound With a pharmaceutical diluent
Which is inert and inserting this mixture into a hard gelatin
capsule having the appropriate siZe. If soft capsules are
desired a slurry of the compound With an acceptable
vegetable, light petroleum, or other inert oil can be encap
sulated by machine into a gelatin capsule.
Suspensions, syrups and elixirs may be used for oral
administration of ?uid unit dosage forms. A?uid preparation
including oil may be used for oil soluble forms. Avegetable

50

the observed angiogenic response. Angiogenesis is quanti
tated by image analysis of vessels and by measuring the
hemoglobin present in the vessels Within the gel.
This approach is used to determine Whether the selected
phosphonic acid agents can inhibit angiogenesis in vivo
using C57B1/6 mice (6 months old). All mice are treated on

55

oil such as corn oil, peanut oil or saf?oWer oil, for example,

together With ?avoring agents, sWeeteners and any preser
vatives produces an acceptable ?uid preparation. A surfac

day 1 of the experimental protocol by injection of 0.2 ml of
Matrigel With a dose of heparin plus bFGF shoWn to induce
intense angiogenesis. The animals are also treated i.p. daily
With 2.0, 0.2 and 0.05 nmoles/20 gram body Weight of
phosphonic acid agents shoWn to be active antiangiogenic
compound in the CAM and HMEC1 all in vitro. The control

group receives daily i.p. injections of physiological saline.

60

tant may be added to Water to form a syrup for ?uid unit

dosages. Hydro-alcoholic pharmaceutical preparations may
be used having an acceptable sWeetener such as sugar,
saccharine or a biological sWeetener and a ?avoring agent in
the form of an elixir.

Pharmaceutical compositions for parenteral and supposi
After ?ve days of treatment, the mice are euthaniZed and 65
dissected. Photographs are taken of the area around the
tory administration can also be obtained using techniques
standard in the art.
Matrigel implants and the gel is removed along With a

6,160,166
35

36

mal parenteral pharmaceutical preparation in a mammal

[yrrolidone and 4-(methyl amino) Butanoic Acid in the
Salmonella/microsome Assay. J. Appl. T0x., 8, 135—139

such as a human. Accordingly, compositions suitable for

(1988). N-methylpyrrolidone has also been shoWn to be an

administration to these areas are particularly included Within

effective penetration enhancer. Barry et al, OptimiZation and
Bioavailability of Topical Steroids: Penetration Enhancers
Under Occlusion. J. Inv. Derm, 82, 49—52 (1984); Akter et
al, Absorption Through human Skin of Ibuprofen and Flur

Another preferred use of the compounds is in a transder

the invention. The above parenteral solutions or suspensions
may be administered transdermally and, if desired a more
concentrated sloW release form may be administered.

Accordingly, incorporation of the active compounds in a
sloW release matrix may be implemented for administering
transdermally. The compounds may be administered trans
dermally at about 1 to 20% of the composition and prefer
ably about 5 to 15% Wt % of the active ingredient in the

biprofen; Effect of Dose Variation, Deposited Drug Films,

vehicle or carrier.

taneous Transport. Int. J. Pharm., 43, 233—240 (1988);
Sugibayashi et al, Effect of Several Penetration Enhancers

Occlusion and the Penetration Enhancer N-methyl-2

pyrrolidone. J. Pharm. PharmacoL, 37, 27—37 (1984); Hole
gaard et al, Vesical Effect on Topical Drug Delivery IV.
Effect of N-methylpyrrolidone and Polar Lipids on Percu

Transdermal therapeutic systems are self-contained dos

age forms that, When applied to intact skin, deliver drug(s)

15

on the Percutaneous Absorption of Indomethacin in Hairless

at a controlled rate to the systemic circulation. Advantages

Rat. Chem. Pharm. BulL, 36, 1519—1529 (1988); Bennett et

of using the transdermal routing include: enhanced thera

al, OptimiZation of Bioavailability of Topical Steroids: Non
occluded penetration Enhancers Under Thermodynamic
Control. J. Pharm. PharmacoL, 37, 298—304 (1985); Sasaki

peutic efficacy, reduction in the frequency of dosing, reduc
tion of side effects due to optimiZation of the blood
concentration versus time pro?le, increased patient

et al, Enhancing Effect of Pyrrolidone Derivatives on Trans

derman Drug Delivery. 1. Ing. J. Pharm., 44, 14—24 (1988);
Lee et al, Toxicity of N-methyl-2-pyrrolidone (NMP):
Teratogenic, Subchronic and TWo-year Inhalation Studies,
Fund. AppL, T0x., 9, 222—235 (1987).

compliance due to elimination of multiple dosing schedules,

bypassing the hepatic “?rst-pass” metabolism, avoiding
gastrointestinal incompatibilities and providing a predict
able and extended duration of activity. HoWever, the main
function of the skin is to act as a barrier to entering 25

compounds. As a consequence, transdermal therapy has so
far been restricted to a limited number of drugs that possess

The pharmaceutical carriers acceptable for the purpose of

the desirable physiochemical properties for diffusion across
the skin barrier. One effective method of overcoming the

this invention are the art knoWn carriers that do not

adversely affect the drug, the host, or the material compris
ing the drug delivery device. Suitable pharmaceutical car

barrier function of the skin is to include a penetration
enhancer in the formulation of a transdermal therapeutic

riers include sterile Water; saline, dextrose; dextrose in Water
or saline; condensation products of castor oil and ethylene
oxide combining about 30 to about 35 moles of ethylene
oxide per mole of castor oil; liquid acid; loWer alkanols; oils

system. See Barry, Brian W.: Dermatological Formulations:

Percutaneous Absorption (Dekker, NeW York, 1983);
Bronough et al, Percutaneous Absorption, Mechanisms

Methodology-Drug Delivery, (Marcel Dekker, NeW York,

The above and other drugs can be present in the reservoir
alone or in combination form With pharmaceutical carriers.

35

NY. 1985); and Monkhouse et al, Transdermal drug deliver

such as corn oil; peanut oil, sesame oil and the like, With
emulsi?ers such as mono- or di-glyceride of a fatty acid, or

problems and promises. Drug Dev. Ind. Pharm., 14, 183—209

a phosphatide, e.g., lecithin, and the like; glycols; polyalky

(1988).

lene glycols; aqueous media in the presence of a suspending

agent, for example, sodium carboxymethylcellulose; sodium
alginate; poly(vinylpyrolidone); and the like, alone, or With
suitable dispensing agents such as lecithin; polyoxyethylene

A penetration enhancer is a chemical compound that,
When included in a formulation, temporarily increases the
permeability of the skin to a drug alloWing more of the drug
to be absorbed in a shorter period of time. Several different
types of penetration enhancers have been reported such as

dimethylsulfoxide, n-decyl methyl sulfoxide, N,N
dimethylacetamide, N,N-dimethylformamide,
1-dodecylaZacycloheptan-2-one (AZone), propylene glycol,

stearate; and the like. The carrier may also contain adjuvants

such as preserving stabiliZing, Wetting, emulsifying agents
and the like together With the penetration enhancer of this
45

ethanol, pyrrolidones such as N-methyl-2-pyrrrolidone
(NMP) and surfactants. See Bronough et al, supra, and

subject being treated. Typically, an effective dosage of a
suramin compound is about 12 g administered for 6 Weeks
(NCI). The phosphonic acid agents may be administered in

Stoughton et al, AZone: a NeW Non-toxic enhancer of

percutaneous penetration. Drug Dev. Inc. Pharm., 9,
725—744 (1983).

a dosage of about 3 g for 6 Weeks.

Compounds of the present invention may be administered
topically at about 1 to 20 Wt % of the composition, and

N-methyl-2-pyrrolidone is a versatile solvent Which is

miscible With Water, ethyl alcohol, ether, chloroform,
benZene, ethyl acetate and carbon disul?de.
N-methylpyrrolidone has been Widely used as a solvent in

55

industrial processes such as petroleum re?ning, GAF Corp.:

“M-Pyrol (N-methyl-2-pyrrolidone) Handbook”, GAF
Corp., NeW York, 1972. It is currently used as a solubiliZing

agent in topical and parenteral veterinary pharmaceuticals
of Double-Labeled [3H and 14C] N-methyl-2-pyrrolidone in
the Rat. Drug Met. Disps., 16, 243—249 (1988). Animal and

line. J. Invest. Dermatol., 99:683, 1992.
Ausprunk D H, D R Knighton, J Folkman. Differentiation

human experiments have shoWn very little irritation or

et al, Mutagenicity and Cytotoxicity of N-methyl-2-p

preferably about 5 to 15 Wt %. Suramin is presently given by
sterile iv. injection because of the poor absorption from the
gut. For suramin treatment of prostate cancer (Stein 1989),
suramin is given iv. (1—2 g/Wk) for a 6 Week treatment
period. The chemical characteristics of the phosphonic acid
agents suggest that higher effective dosages are achievable.
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